TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2020 DA - 2020// TI - Cancer statistics, 2020 JO - CA Cancer J Clin. VL - 70 UR - https://doi.org/10.3322/caac.21590 DO - 10.3322/caac.21590 ID - Siegel2020 ER - TY - JOUR AU - Graham, J. AU - Baker, M. AU - Macbeth, F. AU - Titshall, V. PY - 2008 DA - 2008// TI - Diagnosis and treatment of prostate cancer: Summary of NICE guidance JO - BMJ. VL - 336 UR - https://doi.org/10.1136/bmj.39498.525706.AD DO - 10.1136/bmj.39498.525706.AD ID - Graham2008 ER - TY - JOUR AU - Wong, Y. N. S. AU - Ferraldeschi, R. AU - Attard, G. AU - Bono, J. PY - 2014 DA - 2014// TI - Evolution of androgen receptor targeted therapy for advanced prostate cancer JO - Nat Rev Clin Oncol VL - 11 UR - https://doi.org/10.1038/nrclinonc.2014.72 DO - 10.1038/nrclinonc.2014.72 ID - Wong2014 ER - TY - JOUR AU - Sharifi, N. AU - Dahut, W. L. AU - Steinberg, S. M. AU - Figg, W. D. AU - Tarassoff, C. AU - Arlen, P. PY - 2005 DA - 2005// TI - A retrospective study of the time to clinical endpoints for advanced prostate cancer JO - BJU Int. VL - 96 UR - https://doi.org/10.1111/j.1464-410X.2005.05798.x DO - 10.1111/j.1464-410X.2005.05798.x ID - Sharifi2005 ER - TY - JOUR AU - Moreira, D. M. AU - Howard, L. E. AU - Sourbeer, K. N. AU - Amarasekara, H. S. AU - Chow, L. C. AU - Cockrell, D. C. PY - 2017 DA - 2017// TI - Predicting time from metastasis to overall survival in castration-resistant prostate cancer: results from SEARCH JO - Clin Genitourin Cancer. VL - 15 UR - https://doi.org/10.1016/j.clgc.2016.08.018 DO - 10.1016/j.clgc.2016.08.018 ID - Moreira2017 ER - TY - JOUR AU - Walker, K. Z. AU - Russell, P. J. AU - Kingsley, E. A. AU - Philips, J. AU - Raghavan, D. PY - 1989 DA - 1989// TI - Detection of malignant cells in voided urine from patients with bladder cancer, a novel monoclonal assay JO - J Urol. VL - 142 UR - https://doi.org/10.1016/S0022-5347(17)39172-3 DO - 10.1016/S0022-5347(17)39172-3 ID - Walker1989 ER - TY - JOUR AU - Russell, P. J. AU - Ow, K. T. AU - Tam, P. N. AU - Juarez, J. AU - Kingsley, E. A. AU - Qu, C. F. PY - 2004 DA - 2004// TI - Immunohistochemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer JO - Cancer Immunol Immunother. VL - 53 ID - Russell2004 ER - TY - JOUR AU - Truong, Q. AU - Justiniano, I. O. AU - Nocon, A. L. AU - Soon, J. T. AU - Wissmueller, S. AU - Campbell, D. H. PY - 2016 DA - 2016// TI - Glypican-1 as a biomarker for prostate cancer: isolation and characterization JO - J Cancer. VL - 7 UR - https://doi.org/10.7150/jca.14645 DO - 10.7150/jca.14645 ID - Truong2016 ER - TY - JOUR AU - Häcker, U. AU - Nybakken, K. AU - Perrimon, N. PY - 2005 DA - 2005// TI - Heparan sulphate proteoglycans: the sweet side of development JO - Nat Rev Mol Cell Biol VL - 6 UR - https://doi.org/10.1038/nrm1681 DO - 10.1038/nrm1681 ID - Häcker2005 ER - TY - STD TI - Wang S, Qiu Y, Bai B. The expression, regulation, and biomarker potential of glypican-1 in cancer. Front Oncol. 2019; https://doi.org/10.3389/fonc.2019.00614. ID - ref10 ER - TY - STD TI - Rahbar K, Afshar-Oromieh A, Jadvar H, Ahmadzadehfar H. PSMA Theranostics: current status and future directions. Mol Imaging. 2018. https://doi.org/10.1177/1536012118776068. ID - ref11 ER - TY - JOUR AU - Lightfoot, D. V. AU - Walker, K. K. AU - Boniface, G. R. AU - Hetherington, E. L. AU - Izard, M. E. AU - Russell, P. J. PY - 1991 DA - 1991// TI - Dosimetric and therapeutic studies in nude mice xenograft models with 153Samarium-labelled monoclonal antibody, BLCA-38 JO - Antib Immunoconjugates Radiopharm. VL - 4 ID - Lightfoot1991 ER - TY - JOUR AU - Russell, P. J. AU - Davis, K. AU - Kingsley, E. AU - Humphreys, J. AU - Hanley, J. AU - O’Grady, H. PY - 1994 DA - 1994// TI - Preclinical studies of monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer JO - Cell Biophys. VL - 24–25 UR - https://doi.org/10.1007/BF02789226 DO - 10.1007/BF02789226 ID - Russell1994 ER - TY - JOUR AU - Russell, P. J. AU - Plomley, J. AU - Shon, I. H. AU - O’Grady, H. AU - Pearce, N. PY - 1993 DA - 1993// TI - Monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer JO - Cell Biophys. VL - 22 UR - https://doi.org/10.1007/BF03033865 DO - 10.1007/BF03033865 ID - Russell1993 ER - TY - JOUR AU - Li, Y. AU - Song, E. AU - Rizvi, S. M. A. AU - Power, C. A. AU - Beretov, J. AU - Raja, C. PY - 2009 DA - 2009// TI - Inhibition of micrometastatic prostate cancer cell spread in animal models by213bilabeled multipletargeted α radioimmunoconjugates JO - Clin Cancer Res. VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-08-1203 DO - 10.1158/1078-0432.CCR-08-1203 ID - Li2009 ER - TY - JOUR AU - Gurney, H. AU - Sabanathan, D. AU - Gillatt, D. AU - Poursoultan, P. AU - Ho Shon, K. AU - Walsh, B. PY - 2017 DA - 2017// TI - MILGa-01: a first-in-human study assessing the safety and tolerability of chMIL-38 in metastatic prostate, bladder, and pancreatic cancers JO - J Clin Oncol. VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.6_suppl.e565 DO - 10.1200/JCO.2017.35.6_suppl.e565 ID - Gurney2017 ER - TY - JOUR AU - Jauw, Y. W. S. AU - Menke-van der Houven van Oordt, C. W. AU - Hoekstra, O. S. AU - Hendrikse, H. N. AU - Vugts, D. J. AU - Zijlstra, J. M. PY - 2016 DA - 2016// TI - Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology: what can we learn from initial clinical trials? JO - Front Pharmacol VL - 7 UR - https://doi.org/10.3389/fphar.2016.00131 DO - 10.3389/fphar.2016.00131 ID - Jauw2016 ER - TY - JOUR AU - Tagawa, S. T. AU - Milowsky, M. I. AU - Morris, M. AU - Vallabhajosula, S. AU - Christos, P. AU - Akhtar, N. H. PY - 2013 DA - 2013// TI - Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer JO - Clin Cancer Res. VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-0231 DO - 10.1158/1078-0432.CCR-13-0231 ID - Tagawa2013 ER - TY - STD TI - Pearce AK, Rolfe BE, Russell PJ, Tse BWC, Whittaker AK, Fuchs AV, et al. Development of a polymer theranostic for prostate cancer. Polym Chem. 2014; https://doi.org/10.1039/C4PY00999A. ID - ref19 ER - TY - JOUR AU - Corwin, W. L. AU - Ebrahimi-Nik, H. AU - Floyd, S. M. AU - Tavousi, P. AU - Mandoiu, I. I. AU - Srivastava, P. K. PY - 2017 DA - 2017// TI - Tumor Control Index as a new tool to assess tumor growth in experimental animals JO - J Immunol Methods. VL - 445 UR - https://doi.org/10.1016/j.jim.2017.03.013 DO - 10.1016/j.jim.2017.03.013 ID - Corwin2017 ER - TY - JOUR AU - Stone, K. R. AU - Mickey, D. D. AU - Wunderli, H. AU - Mickey, G. H. AU - Paulson, D. F. PY - 1978 DA - 1978// TI - Isolation of a human prostate carcinoma cell line (DU 145) JO - Int J Cancer. VL - 21 UR - https://doi.org/10.1002/ijc.2910210305 DO - 10.1002/ijc.2910210305 ID - Stone1978 ER - TY - JOUR AU - Boyle, C. C. AU - Paine, A. J. AU - Mather, S. J. PY - 1992 DA - 1992// TI - The mechanism of hepatic uptake of a radiolabelled monoclonal antibody JO - Int J Cancer. VL - 50 UR - https://doi.org/10.1002/ijc.2910500616 DO - 10.1002/ijc.2910500616 ID - Boyle1992 ER - TY - JOUR AU - Koizumi, M. AU - Endo, K. AU - Watanabe, Y. AU - Saga, T. AU - Sakahara, H. AU - Konishi, J. PY - 1989 DA - 1989// TI - Pharmacokinetics of internally labeled monoclonal antibodies as a gold standard: comparison of biodistribution of 75Se-, 111In-, and 125I-labeled monoclonal antibodies in osteogenic sarcoma xenografts in nude mice JO - Cancer Res. VL - 49 ID - Koizumi1989 ER - TY - JOUR AU - Lee, S. AU - Kim, J. H. AU - Lee, J. H. AU - Zen, Y. AU - Han, J. K. PY - 2017 DA - 2017// TI - Imaging monitoring of Kupffer cell function and hepatic oxygen saturation in preneoplastic changes during cholangiocarcinogenesis JO - Sci Rep. VL - 7 UR - https://doi.org/10.1038/s41598-017-14218-x DO - 10.1038/s41598-017-14218-x ID - Lee2017 ER - TY - JOUR AU - Li, M. AU - Tang, Y. AU - Yao, J. PY - 2018 DA - 2018// TI - Photoacoustic tomography of blood oxygenation: a mini review JO - Photoacoustics. VL - 10 UR - https://doi.org/10.1016/j.pacs.2018.05.001 DO - 10.1016/j.pacs.2018.05.001 ID - Li2018 ER - TY - JOUR AU - Matsuzaki, S. AU - Serada, S. AU - Hiramatsu, K. AU - Nojima, S. AU - Matsuzaki, S. AU - Ueda, Y. PY - 2018 DA - 2018// TI - Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer JO - Int J Cancer. VL - 142 UR - https://doi.org/10.1002/ijc.31124 DO - 10.1002/ijc.31124 ID - Matsuzaki2018 ER - TY - JOUR AU - Harada, E. AU - Serada, S. AU - Fujimoto, M. AU - Takahashi, Y. AU - Takahashi, T. AU - Hara, H. PY - 2017 DA - 2017// TI - Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma JO - Oncotarget. VL - 8 ID - Harada2017 ER - TY - JOUR AU - Jen, Y. H. L. AU - Musacchio, M. AU - Lander, A. D. PY - 2009 DA - 2009// TI - Glypican-1 controls brain size through regulation of fibroblast growth factor signaling in early neurogenesis JO - Neural Dev. VL - 4 UR - https://doi.org/10.1186/1749-8104-4-33 DO - 10.1186/1749-8104-4-33 ID - Jen2009 ER - TY - JOUR AU - Levin, R. A. AU - Lund, M. E. AU - Truong, Q. AU - Wu, A. AU - Shore, N. D. AU - Saltzstein, D. R. PY - 2018 DA - 2018// TI - Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker JO - Oncotarget. VL - 9 ID - Levin2018 ER - TY - JOUR AU - Emmett, L. AU - Willowson, K. AU - Violet, J. AU - Shin, J. AU - Blanksby, A. AU - Lee, J. PY - 2017 DA - 2017// TI - Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy JO - J Med Radiat Sci. VL - 64 UR - https://doi.org/10.1002/jmrs.227 DO - 10.1002/jmrs.227 ID - Emmett2017 ER - TY - JOUR AU - Hofman, M. S. AU - Violet, J. AU - Hicks, R. J. AU - Ferdinandus, J. AU - Ping Thang, S. AU - Akhurst, T. PY - 2018 DA - 2018// TI - [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study JO - Lancet Oncol. VL - 6 UR - https://doi.org/10.1016/S1470-2045(18)30198-0 DO - 10.1016/S1470-2045(18)30198-0 ID - Hofman2018 ER - TY - JOUR AU - Bräuer, A. AU - Grubert, L. S. AU - Roll, W. AU - Schrader, A. J. AU - Schäfers, M. AU - Bögemann, M. PY - 2017 DA - 2017// TI - 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer JO - Eur J Nucl Med Mol Imaging. VL - 44 UR - https://doi.org/10.1007/s00259-017-3751-z DO - 10.1007/s00259-017-3751-z ID - Bräuer2017 ER - TY - JOUR AU - Tagawa, S. T. AU - Vallabhajosula, S. AU - Christos, P. J. AU - Jhanwar, Y. S. AU - Batra, J. S. AU - Lam, L. PY - 2019 DA - 2019// TI - Phase 1/2 study of fractionated dose lutetium-177–labeled anti–prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer JO - Cancer. VL - 125 ID - Tagawa2019 ER - TY - JOUR AU - Lu, H. AU - Niu, F. AU - Liu, F. AU - Gao, J. AU - Sun, Y. AU - Zhao, X. PY - 2017 DA - 2017// TI - Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma JO - Cancer Med. VL - 6 UR - https://doi.org/10.1002/cam4.1064 DO - 10.1002/cam4.1064 ID - Lu2017 ER - TY - JOUR AU - Matsuda, K. AU - Maruyama, H. AU - Guo, F. AU - Kleeff, J. AU - Itakura, J. AU - Matsumoto, Y. PY - 2001 DA - 2001// TI - Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells JO - Cancer Res. VL - 61 ID - Matsuda2001 ER - TY - JOUR AU - Saito, T. AU - Sugiyama, K. AU - Hama, S. AU - Yamasaki, F. AU - Takayasu, T. AU - Nosaka, R. PY - 2017 DA - 2017// TI - High expression of glypican-1 predicts dissemination and poor prognosis in glioblastomas JO - World Neurosurg. VL - 105 UR - https://doi.org/10.1016/j.wneu.2017.05.165 DO - 10.1016/j.wneu.2017.05.165 ID - Saito2017 ER - TY - JOUR AU - Hara, H. AU - Takahashi, T. AU - Serada, S. AU - Fujimoto, M. AU - Ohkawara, T. AU - Nakatsuka, R. PY - 2016 DA - 2016// TI - Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma JO - Br J Cancer. VL - 115 UR - https://doi.org/10.1038/bjc.2016.183 DO - 10.1038/bjc.2016.183 ID - Hara2016 ER - TY - JOUR AU - Amatya, V. J. AU - Kushitani, K. AU - Kai, Y. AU - Suzuki, R. AU - Miyata, Y. AU - Okada, M. PY - 2018 DA - 2018// TI - Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma JO - Mod Pathol. VL - 31 UR - https://doi.org/10.1038/modpathol.2017.190 DO - 10.1038/modpathol.2017.190 ID - Amatya2018 ER - TY - JOUR AU - Chiu, K. AU - Lee, L. AU - Cheung, S. AU - Churg, A. M. PY - 2018 DA - 2018// TI - Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma JO - Mod Pathol. VL - 31 UR - https://doi.org/10.1038/s41379-018-0066-y DO - 10.1038/s41379-018-0066-y ID - Chiu2018 ER -